Free Trial

Onconetix (ONCO) Competitors

Onconetix logo
$2.97 -0.03 (-1.00%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$3.04 +0.07 (+2.53%)
As of 09/19/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ONCO vs. EDSA, CLRB, MTVA, IBIO, IXHL, NRSN, THAR, AIMD, LPCN, and BLRX

Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Edesa Biotech (EDSA), Cellectar Biosciences (CLRB), MetaVia (MTVA), iBio (IBIO), Incannex Healthcare (IXHL), NeuroSense Therapeutics (NRSN), Tharimmune (THAR), Ainos (AIMD), Lipocine (LPCN), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry.

Onconetix vs. Its Competitors

Edesa Biotech (NASDAQ:EDSA) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Edesa Biotech has a net margin of 0.00% compared to Onconetix's net margin of -3,327.03%. Edesa Biotech's return on equity of -162.95% beat Onconetix's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -162.95% -60.33%
Onconetix -3,327.03%-192.74%-89.55%

In the previous week, Edesa Biotech's average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company Overall Sentiment
Edesa Biotech Neutral
Onconetix Neutral

Edesa Biotech has higher earnings, but lower revenue than Onconetix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$6.17M-$1.32-1.87
Onconetix$2.52M1.83-$58.69MN/AN/A

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 22.6% of Edesa Biotech shares are owned by insiders. Comparatively, 3.1% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Edesa Biotech presently has a consensus target price of $5.00, suggesting a potential upside of 102.43%. Given Edesa Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Edesa Biotech is more favorable than Onconetix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Onconetix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Edesa Biotech has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500.

Summary

Edesa Biotech beats Onconetix on 8 of the 11 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCO vs. The Competition

MetricOnconetixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.64M$3.16B$5.79B$10.40B
Dividend YieldN/A2.37%5.63%4.60%
P/E RatioN/A20.5276.4826.75
Price / Sales1.83446.54531.72124.23
Price / CashN/A46.0037.9261.55
Price / Book0.269.6613.726.40
Net Income-$58.69M-$53.02M$3.29B$271.62M
7 Day Performance-2.62%3.12%2.65%3.46%
1 Month Performance8.79%7.57%6.01%9.87%
1 Year Performance-98.94%11.17%80.02%28.45%

Onconetix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCO
Onconetix
0.3201 of 5 stars
$2.97
-1.0%
N/A-99.2%$4.64M$2.52M0.0012
EDSA
Edesa Biotech
1.206 of 5 stars
$2.41
-0.4%
$5.00
+107.5%
-43.2%$16.97MN/A-1.8320
CLRB
Cellectar Biosciences
2.9823 of 5 stars
$5.29
+5.2%
$375.00
+6,988.8%
-91.8%$16.88MN/A-0.2710Short Interest ↓
Gap Up
MTVA
MetaVia
1.8001 of 5 stars
$0.68
-1.8%
$7.50
+1,006.2%
N/A$16.41MN/A0.008News Coverage
IBIO
iBio
1.6409 of 5 stars
$0.83
-2.6%
$5.00
+500.4%
-54.3%$16.37M$375K-0.48100
IXHL
Incannex Healthcare
0.0336 of 5 stars
$0.55
-6.3%
N/A-72.4%$16.05M$10K-0.453
NRSN
NeuroSense Therapeutics
2.2092 of 5 stars
$1.17
+0.9%
$14.00
+1,096.6%
-9.6%$15.99MN/A-2.1710
THAR
Tharimmune
2.5525 of 5 stars
$2.79
-5.7%
$17.00
+509.3%
+20.4%$15.88MN/A-0.462Gap Down
AIMD
Ainos
0.9564 of 5 stars
$3.38
-6.4%
N/A+52.5%$15.75M$20K-0.6840News Coverage
LPCN
Lipocine
2.7648 of 5 stars
$2.88
-1.0%
$9.00
+212.5%
-39.6%$15.61M$4.21M-3.3110Gap Up
BLRX
BioLineRx
2.6276 of 5 stars
$3.61
-0.8%
$26.00
+620.2%
-85.7%$15.38M$28.94M-0.4140

Related Companies and Tools


This page (NASDAQ:ONCO) was last updated on 9/20/2025 by MarketBeat.com Staff
From Our Partners